News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
Teva Pharmaceutical Industries Limited Announces Two Court Decisions to Revoke MSD’s European Patent on Generic Fosamax(R)
February 25, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (Ticker: TEVA) announced the following decisions by two European courts:
Twitter
LinkedIn
Facebook
Email
Print
Legal
Asia
MORE ON THIS TOPIC
Legal
Lilly cracks down on black market for obesity asset retatrutide with six lawsuits
August 12, 2026
·
2 min read
·
Tristan Manalac
Manufacturing
AstraZeneca partners with CSPC to build Chinese biologics manufacturing plant
August 10, 2026
·
2 min read
·
Nick Paul Taylor
Regulatory
Lilly, FDA retatrutide biologic dispute comes to a head as submission nears
August 5, 2026
·
3 min read
·
Annalee Armstrong
Cancer
Pathos inks back-to-back cancer contracts with AstraZeneca, China’s Alphamab
August 4, 2026
·
2 min read
·
Tristan Manalac
